Oral probiotic hydrogel as well as preparation method and application thereof

By encapsulating probiotics in inulin-modified thiolated polysaccharide hydrogels, the problem of probiotics being easily inactivated in the gastrointestinal tract is solved, achieving colon-targeted and highly efficient release of probiotics and enhancing the therapeutic effect on related diseases.

CN121102122APending Publication Date: 2025-12-12ZHEJIANG UNIV OF TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511033554.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-25
Publication Date
2025-12-12

AI Technical Summary

Technical Problem

Currently, probiotics are easily inactivated by the gastrointestinal environment during oral administration, resulting in poor therapeutic effects. Furthermore, existing delivery systems suffer from problems such as high fragility, slow release, or difficulty in self-assembly.

Method used

Probiotics are encapsulated in inulin-modified thiolated polysaccharide hydrogels, which are cross-linked by disulfide bonds to form hydrogels and enhanced by hydrogen bonds to increase gel strength. This process protects the probiotics in the gastrointestinal tract and allows for specific dissociation and release in the colon, enhancing colon targeting.

Benefits of technology

It improves the survival rate and colon targeting of probiotics in the gastrointestinal tract, promotes the colonization and immunomodulatory effects of probiotics in the intestine, and enhances the therapeutic effect, especially for diseases such as irritable bowel syndrome, diarrhea, constipation, indigestion, inflammatory bowel disease, colon cancer, diabetes, obesity, and hypercholesterolemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121102122A_ABST
    Figure CN121102122A_ABST
Patent Text Reader

Abstract

The invention relates to oral probiotic hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing inulin-modified thiolated polysaccharide with a probiotic liquid, and quickly crosslinking to form probiotic hydrogel, so as to construct a colon-targeted probiotic delivery system; the system can effectively protect the probiotics from passing through the upper digestive tract, and realizes targeted release of the probiotics at the colon part by using a dual mechanism that the inulin is specifically ingested by the probiotics in the colon and the disulfide bond is easily reduced and disassembled by reduced glutathione (GSH) in the colon. The oral probiotic hydrogel disclosed by the invention is applied to preparation of medicines for preventing and treating irritable bowel syndrome, diarrhea, constipation, dyspepsia, inflammatory bowel disease, colon cancer, diabetes mellitus, obesity and hypercholesteremia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedicine, and in particular to an oral probiotic hydrogel, its preparation method, and its application. Background Technology

[0002] The gut microbiota not only maintains intestinal homeostasis through complex ecological interactions, but also plays a central role in regulating host health. For example, short-chain fatty acids produced by Firmicutes can directly participate in maintaining intestinal barrier integrity and regulating host energy metabolism and immune homeostasis; Bacteroidetes participate in the regulation of host glucose and lipid metabolism by breaking down dietary fiber; and vitamins and immunomodulatory factors synthesized by Actinobacteria directly affect host nutrient absorption and immune response. When this micro-ecosystem is imbalanced, it triggers a cascade of pathological responses. For example, in patients with inflammatory bowel disease (IBD), the abundance of probiotic Firmicutes is significantly reduced, while pathogenic Enterobacteriaceae proliferate abnormally. The mucosal barrier damage mediated by this can activate the TLR4 / TRAF6 / NF-κB inflammatory pathway, accelerating intestinal epithelial lesions. In patients with ulcerative colitis (UC), the abundance of Lactobacillus is significantly reduced, while Bacteroidetes and facultative anaerobes proliferate excessively. This dysbiosis not only damages the intestinal mucosal barrier but also exacerbates the inflammatory response and even promotes carcinogenesis by continuously activating the NF-κB signaling pathway. In terms of metabolic diseases, obese patients have significantly reduced intestinal fungal diversity, among which the overgrowth of opportunistic pathogens such as Candida is closely related to a chronic low-grade inflammatory state.

[0003] Currently, treatments for these diseases mainly include chemical drugs, antibiotics, and probiotics. However, chemical drugs often have significant systemic side effects, and long-term use of antibiotics can not only alter the abundance of disease-related microbial communities but also lead to drug resistance. Probiotics, as an important microecological regulator, exhibit unique therapeutic advantages in stabilizing intestinal microecological balance, enhancing intestinal barrier function, regulating the immune system, and intervening in metabolism. However, oral administration of probiotics faces many challenges, such as the low pH environment of the gastrointestinal tract and physiological barriers like digestive enzymes and bile salts, which can easily cause probiotics to become inactive before reaching their target sites, thus significantly reducing their therapeutic efficacy. Therefore, improving the bioactivity of probiotics during oral administration has become crucial for treating gastrointestinal diseases with oral probiotics. Currently used encapsulation methods include liposome encapsulation, surface chemical coating, and hydrogel encapsulation. However, liposome encapsulation may cause premature leakage of probiotics due to the action of bile salts in the body; surface chemical coating may reduce the activity of probiotics due to excessive surface coating. In contrast, hydrogel delivery systems based on natural polysaccharides have good biocompatibility, degradability, and controllable release. Furthermore, the three-dimensional network structure formed by cross-linking through electrostatic or hydrogen bonding between polysaccharides has good adjustable flowability and can provide nutrients for the encapsulated probiotics.

[0004] Patent CN116712403A mentions an aerogel microcapsule for colon-targeted delivery of probiotics, which has the problems of high brittleness, fragility, and slow release; patent CN119925297A mentions a synbiotic gel microcapsule, which uses an inulin-gelatin system without thiol modification, making it difficult to self-assemble into a hydrogel at room temperature. Summary of the Invention

[0005] One object of the present invention is to provide an oral probiotic hydrogel delivery system, which encapsulates probiotics in a polysaccharide hydrogel to prevent the oral probiotics from being inactivated in the gastrointestinal tract and to promote the colonic targeting of the probiotics or their loaded drugs, thereby achieving better therapeutic effects.

[0006] Another objective of this invention is to provide a method for preparing oral probiotic hydrogels, which has the advantages of being simple, rapid, and having a mild reaction.

[0007] Another objective of this invention is to provide an application of an oral probiotic hydrogel, which provides the application of probiotics in the preparation of drugs for the prevention and treatment of irritable bowel syndrome, diarrhea, constipation, indigestion, inflammatory bowel disease, colon cancer, diabetes, obesity, and hypercholesterolemia.

[0008] To achieve the above objectives, this invention provides an oral probiotic hydrogel, comprising an inulin-modified terminal thiolized polysaccharide hydrogel and probiotics. The thiol groups in the inulin-modified thiolized polysaccharide can be converted into disulfide bonds, thus cross-linking together. These disulfide bonds are reversible and can be specifically dissociated. Furthermore, hydrogen bonds and the molecular chains in inulin can help enhance gel strength. The inulin-modified thiolized polysaccharide rapidly cross-links under mild conditions to form a hydrogel encapsulating the probiotics, effectively protecting them from the harmful gastrointestinal environment. The redox-responsive properties of the hydrogel allow for specific dissociation in the colonic reducing environment, enabling effective release of the probiotics. In particular, the inulin in this system not only enhances the colonic targeting properties of the hydrogel, but also, as a prebiotic, can be selectively utilized by the released probiotics, promoting bacterial colonization and stimulating the production of short-chain fatty acids (SCFAs), exerting immunomodulatory effects and enhancing the therapeutic effects of the probiotics.

[0009] As a preferred option, the terminally thiolized polysaccharide modified with inulin has the following structural formula: In this structure, R is a repeating polysaccharide unit containing a carboxylic acid. The carboxyl-containing polysaccharide can be any one of hyaluronic acid, carboxymethyl chitosan, alginate, pectin, xanthan gum, carboxymethyl cellulose, carboxymethyl glucose, carboxymethyl starch, or chondroitin sulfate. This polysaccharide structure contains an inulin structure and terminal thiol groups. These thiol groups can rapidly cross-link to form a hydrogel. Inulin can form hydrogen bonds with the hydroxyl and carboxyl oxygen atoms on adjacent polysaccharide chains, enhancing the stability and mechanical strength of the hydrogel, thus better encapsulating probiotics.

[0010] Preferably, the probiotics are one or more subspecies of probiotics from the genera *Lactobacillus*, *Bifidobacterium*, *Enterococcus*, *Lactococcus lactis*, *Clostridium butyricum*, and *Bacillus*.

[0011] Preferably, the terminal thiolized polysaccharide modified with inulin is prepared by reacting inulin, polysaccharide, and L-cysteine ​​methyl ester hydrochloride; the molar ratio of carboxyl groups in inulin and polysaccharide is 1:20-1:1; and the molar ratio of carboxyl groups to L-cysteine ​​methyl ester hydrochloride in the inulin-modified polysaccharide is 0.1:1-2:1.

[0012] A method for preparing an oral probiotic hydrogel includes the following steps: S1. The polysaccharide was pretreated, then inulin was added, and the mixture was mixed and reacted under nitrogen for a period of time. After dialysis and freeze-drying, inulin-modified polysaccharide was obtained. S2. After treating the inulin-modified polysaccharide, L-cysteine ​​methyl ester hydrochloride was added, the pH was adjusted, and the mixture was mixed and reacted under nitrogen for a period of time. After the reaction was completed, the mixture was dialyzed and freeze-dried to obtain the inulin-modified thiolated polysaccharide. S3. Resuspend the centrifuged probiotics in sterile water to obtain bacterial solutions of different concentrations. Add the inulin-modified thiolated polysaccharide obtained in S2, mix well, and let stand to prepare probiotic hydrogels of different concentrations.

[0013] Preferably, the pretreatment of polysaccharides in step S1 involves dissolution and activation; the treatment of inulin-modified polysaccharides in step S2 involves dissolution and activation; the solvent in step S1 is dimethyl sulfoxide, the activator is N,N'-carbonyldiimidazole, and the molar ratio of N,N'-carbonyldiimidazole to polysaccharides is 0.3:1-1:1; the solvent in step S2 is water, the activator is N-hydroxysuccinimide (NHS) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCl), the molar ratio of NHS to inulin-modified polysaccharides is 2:1-10:1, and the molar ratio of EDCl to inulin-modified polysaccharides is 2:1-10:1.

[0014] Preferably, in step S1 the reaction temperature is 15-25℃ and the reaction time is 12-72h; in step S2 the pH value is adjusted to 3-6, the reaction temperature is 15-25℃, and the reaction is carried out in the dark for 1-4h.

[0015] Preferably, the concentration of the probiotic solution in step S3 is 1×10⁻⁶. 6 ~1×10 10 CFU / ml.

[0016] Preferably, the dialysis conditions in step S1 are: dialysis for 4 days with a dialysis bag (MWCO: 8000-14000Da), freeze-drying for 2 days, and cold trap temperature of -60°C; the dialysis in step S2 is: dialysis twice with pH 5.0 hydrochloric acid solution, followed by dialysis once with pH 5.0 hydrochloric acid solution containing 1% (w / v) NaCl, and then dialysis twice with pH 5.0 hydrochloric acid solution, freeze-drying for 1 day, and cold trap temperature of -60°C.

[0017] The application of an oral probiotic hydrogel in the preparation of drugs for the prevention and treatment of irritable bowel syndrome, diarrhea, constipation, indigestion, inflammatory bowel disease, colon cancer, diabetes, obesity, and hypercholesterolemia.

[0018] In summary, the present invention has the following technical effects:

[0019] The oral probiotic hydrogel of the present invention utilizes a polysaccharide hydrogel to efficiently encapsulate probiotics, effectively overcoming the technical challenge of easy inactivation of oral probiotics in the gastrointestinal environment and improving the colon-targeting ability of probiotics, thereby significantly improving the therapeutic effect.

[0020] The oral probiotic hydrogel of the present invention can effectively release probiotics in the colon and play a role in regulating the intestinal microecology. In addition, inulin can be taken up by microorganisms to produce SCFAs, which stimulate the intestinal immune response and play a beneficial role such as anti-inflammation, thereby achieving a synergistic therapeutic effect of targeted therapy and microecological regulation.

[0021] The oral probiotic hydrogel of this invention has applications in the preparation of drugs for the prevention and treatment of irritable bowel syndrome, diarrhea, constipation, indigestion, inflammatory bowel disease, colon cancer, diabetes, obesity, and hypercholesterolemia. Furthermore, drugs or nanomedicines can be mounted on the probiotics to achieve therapeutic effects for other diseases.

[0022] The method for preparing oral probiotic hydrogel of the present invention can effectively modify inulin onto polysaccharides, effectively add thiol groups to polysaccharides, and effectively prepare an oral probiotic hydrogel. Attached Figure Description

[0023] Figure 1Inulin-modified thiolated hyaluronic acid (IHS) 1 H-NMR spectrum (400MHz, D2O).

[0024] Figure 2 FT-IR spectra of hyaluronic acid (HA), inulin (IN), and IHS.

[0025] Figure 3 (A) is a SEM image of IHS / BI-PINPs, and (B) is a magnified SEM image of the red area in Figure A.

[0026] Figure 4 The rheological dynamic scanning curves of different concentrations of IHS at 37℃, 10 rad / s and 1% strain are shown.

[0027] Figure 5 Rheological dynamic scanning curves of different concentrations of IHS at different temperatures, 10 rad / s, and 1% strain are presented.

[0028] Figure 6 The rheological dynamic scanning curves of different concentrations of IHS at different frequencies are shown.

[0029] Figure 7 The rheological dynamic scanning curves of 4% IHS hydrogels after being placed in different concentrations of glutathione (GSH) for 6 hours are shown at different frequencies.

[0030] Figure 8 Degradation curves of 4% and 8% IHS in simulated gastric fluid (SGF, pH 2.0, containing pepsin).

[0031] Figure 9 The degradation curves of 8% IHS in PBS (pH 7.8) and glutathione-containing simulated colonic fluid (SCF, pH 7.8) are shown.

[0032] Figure 10 The number of surviving bacteria after gastrointestinal treatment (SGF 3h + SIF 4h + SCF 6h) of IHS-encapsulated Bifidobacterium infantis (BI) hydrogels at different concentrations (initial BI input: 4×10⁻⁶) 9 CFU).

[0033] Figure 11 The number of Bifidobacterium infantis hydrogels encapsulated with different concentrations of IHS after treatment with 0.5% bile salts for 4 hours (initial BI input: 4 × 10⁻⁶). 9 CFU).

[0034] Figure 12 This graph shows the number of bacteria that survived after freeze-dried BI and IHS / BI were stored at -80°C for different times.

[0035] Figure 13 Transmission electron microscopy schematic diagrams of (A) BI, (B) irinotecan (IRT)-loaded polydopamine nanoparticles (PINPs), and (C, D) BI-PINPs.

[0036] Figure 14 Bacterial survival rate of BI-PINPs and 4% IHS / BI-PINPs after gastrointestinal conditioning (SGF 3h + SIF 4h + SCF 6h) (initial BI level: 3.5 × 10⁻⁶) 9 CFU).

[0037] Figure 15 A graph showing the survival rate of BI in lyophilized BI-PINPs and IHS / BI-PINPs stored at 4°C for different times (initial BI quantity: 4 × 10⁻⁶). 8 CFU).

[0038] Figure 16 The cumulative drug release curves of IHS / BI-PINPs in SGF, SIF and simulated colon tumor microenvironment (SCF containing 10 mMMGSH, 10 U / mL inulinase at pH 6.5) are shown.

[0039] Figure 17 The curves showing the changes in body weight of mice with orthotopic colon cancer during treatment with different formulations (n=4).

[0040] Figure 18 The gastrointestinal tract of mice with orthotopic colon cancer after 14 days of treatment with different formulations is shown in the diagram (tumors are marked with circles and arrows, n=4).

[0041] Figure 19 A statistical graph showing the number of metastatic tumor nodules in the gastrointestinal tract of mice in each group after treatment (n=4).

[0042] Figure 20 The tumor inhibition rate is plotted for each treatment group (n=4).

[0043] Figure 21 H&E stained sections of tumors from mice in each group (scale bar: 50 μm).

[0044] Figure 22 H&E stained sections of various tissues and organs from different groups of tumor-bearing mice. Detailed Implementation

[0045] The technical solution of the present invention will be further described below with reference to the accompanying drawings and embodiments.

[0046] To make the objectives, technical solutions, and advantages of this application clearer, more thorough, and more complete, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings and embodiments. The following detailed descriptions are all illustrations of embodiments, intended to provide further detailed explanation of the present invention. Unless otherwise specified, all technical terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains.

[0047] Example 1

[0048] The present invention discloses an oral probiotic hydrogel delivery system, comprising probiotics and a polysaccharide hydrogel encapsulating the probiotics.

[0049] Specifically, the probiotics are one or more subspecies of probiotics from the genera *Lactobacillus*, *Bifidobacterium*, *Enterococcus*, *Lactococcus lactis*, *Clostridium butyricum*, and *Bacillus*. The *Bifidobacterium* genus includes one of the following: *Bifidobacterium longum*, *Bifidobacterium breve*, *Bifidobacterium bifidum*, *Bifidobacterium adolescentis*, *Bifidobacterium infantis*, *Bifidobacterium thermophilum*, *Bifidobacterium animalis*, *Bifidobacterium lactis*, *Bifidobacterium asteroides*, *Bifidobacterium chainiensis*, and *Bifidobacterium densiflorum*. In this embodiment, *Bifidobacterium infantis* is selected.

[0050] The encapsulated probiotic polysaccharides include hyaluronic acid, carboxymethyl chitosan, alginate, pectin, xanthan gum, carboxymethyl cellulose, carboxymethyl glucose, carboxymethyl starch, and chondroitin sulfate. Hyaluronic acid is used in this embodiment.

[0051] Example 2

[0052] Inulin-modified hyaluronic acid was prepared using hyaluronic acid.

[0053] 1 g of hyaluronic acid (HA, Mw 100-200 kDa, containing 2.5 mmol carboxyl groups) was dissolved in 10 mL of ultra-dry DMSO. 243 mg (1.5 mmol) of N,N'-carbonyldiimidazole was added, and the mixture was reacted at room temperature under nitrogen protection for 48 h to fully activate the carboxyl groups of HA. Then, 0.125–1.125 mmol of inulin (IN) was dissolved in ultra-dry DMSO. The activated HA was slowly added to the IN solution, and the mixture was reacted at room temperature under nitrogen protection for 12–72 h. Afterward, the mixture was transferred to a dialysis bag for dialyzing, and then freeze-dried to obtain the inulin-hyaluronic acid complex (IH).

[0054] Example 3

[0055] Inulin-modified hyaluronic acid is thiolated.

[0056] 125 mg of IH was dissolved in 25 mL of deionized water, and 143.86 (1.25 mmol) of N-hydroxysuccinimide (NHS) and 239.5 mg (1.25 mmol) of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCl) were added. The pH was adjusted to 4, and the mixture was reacted at room temperature in the dark for 2 h to activate the carboxyl group in IN-HA. Then, 0.273–1.638 mmol of L-cysteine ​​methyl ester hydrochloride was added to the mixture, and the pH of the solution was adjusted to 3–8. The mixture was reacted at room temperature in the dark under nitrogen protection for 24 h, and then dialyzed. After the reaction was completed, the mixture was freeze-dried to obtain the terminally thiolized inulin-hyaluronic acid complex (IHS).

[0057] The inulin-modified thiolized hyaluronic acid prepared in this embodiment 1 H-NMR and FT-IR spectra are attached. Figure 1 , 2 As shown, 1 ¹H-NMR showed a proton peak at 1.95 ppm for the N-acetyl group of HA, peaks at 2.350 ppm and 2.607 ppm indicating the presence of a methylene proton in the -CH₂CH₂SH group in the synthesized product, and a peak at 2.823 ppm due to the presence of the -COOCH₃ moiety. FT-IR showed a peak at 1557 cm⁻¹. -1 The peak at 2520 cm⁻¹ is a characteristic peak of -NH in IHS. -1 An additional -SH stretching vibration peak was observed. These results demonstrate the successful synthesis of inulin-modified thiolated hyaluronic acid.

[0058] Example 4

[0059] Preparation of probiotic hydrogels.

[0060] 8 mg, 12 mg, and 16 mg of IHS conjugate were dissolved in 200 μL of PBS, respectively, and the pH was adjusted to 7.4. The mixtures were then vortexed and incubated at 37 °C to allow complete hydrogel formation. A series of 4%, 6%, and 8% hydrogels were prepared using the above method.

[0061] Bifidobacterium infantis cultured to the logarithmic growth phase was diluted with sterile water to obtain 1.0 × 10⁻⁶ ppm. 6 -1.0×10 10 CFU / ml bacterial solution was added to IHS, vortexed to mix evenly, and allowed to stand to prepare 4%, 6%, and 8% probiotic hydrogels.

[0062] like Figure 3The hydrogel shown has a three-dimensional porous structure, with probiotics evenly distributed in the hydrogel channels. As shown by the magnified partial image, the hydrogel encapsulation does not significantly change the surface morphology of the drug-loaded probiotics. The probiotics encapsulated in the hydrogel still exhibit their own morphology, which is short rod-shaped.

[0063] Example 1

[0064] The effects of the hydrogel prepared in Example 4 were investigated.

[0065] Determination of rheological properties of redox-sensitive hydrogels.

[0066] The rheological properties of hydrogels with different concentrations in Example 4 were investigated using a rotational rheometer. A parallel plate with a diameter of 25 mm was used as a mold, and the test gap was 100 μm. With control of the corresponding variables, the storage modulus (G') and loss modulus (G”) of hydrogels formed by 4%, 6%, and 8% IHS were tested as a function of time, temperature, and frequency.

[0067] like Figure 4 As shown, based on the dynamic scanning curves of hydrogels formed by different concentrations of IHS at 37℃, 10 rad / s, and 1% strain, it can be seen that G' is always greater than G", indicating that IHS forms hydrogels with a good three-dimensional network structure. Figure 5 As shown, the modulus of the hydrogel did not change significantly under different temperatures, 10 rad / s, and 1% strain, indicating that the hydrogel possesses a certain degree of thermal stability. Figure 6 As shown, the storage modulus of the hydrogel increases with increasing frequency under 1% strain, exhibiting typical elastic deformation. G' is always greater than G", indicating that it has stable mechanical properties.

[0068] Example 2

[0069] Determination of redox degradation behavior.

[0070] Using reduced glutathione (GSH) as a solvent, the redox degradation behavior of the 4% IHS hydrogel in Example 4 was investigated under different concentrations of reducing agent. The fully gelled hydrogel was immersed in different concentrations (10 μM, 5 mM, 10 mM) of GSH and allowed to stand for 6 h. After 6 h, it was removed and placed in a rotational rheometer to measure G' and G'' in the frequency range of 0.1–100 rad / s under 37 °C and 1% strain conditions. The results are as follows: Figure 7As shown, the G' of the gels increases with increasing frequency, consistent with the inherent properties of gels. However, it is evident that the gel with the highest G' is in 10 μM glutathione, indicating that the gel can maintain its intact structure under normal physiological conditions. When the GSH concentration is 10 mM, the G' decreases by nearly half. The hydrogel in 5 mM GSH exhibits better elasticity than the hydrogel in 10 mM GSH. This is because higher GSH concentrations increase the probability of disulfide bond reduction, leading to disulfide bond breakage and alteration of the hydrogel's internal structure. This may involve polymer chain breakage and disulfide bond breakage, resulting in structural collapse. Therefore, hydrogels are easily degraded at high GSH concentrations.

[0071] Example 3

[0072] Degradation of hydrogels in simulated gastric juice and glutathione-containing colonic juice.

[0073] To evaluate the colonic release capacity of the hydrogel in Example 4, its disintegration ability in simulated gastric juice and colonic juice containing glutathione and enzymes was investigated. The steps included: preparing the degradation medium: simulated gastric juice (SGF) at pH 2.0; PBS buffer at pH 7.8; and simulated colonic juice (SCF) at pH 7.8 containing 10 mM GSH and 10 U / mL inulinase. Fresh hydrogels of different concentrations were prepared, their initial mass (M0) was weighed, and then placed in the above degradation medium. The samples were incubated at 37°C with shaking at 100 rpm, removed at fixed intervals, and the surface moisture was blotted dry with filter paper. The wet weight (M1) was measured to obtain the degradation rate, and a degradation curve was plotted.

[0074] like Figure 8 As shown, the degradation rate of 4% IHS in simulated gastric fluid was more significant than that of 8% IHS, but the degradation rate was less than 20%, and the wet weight of the hydrogel remained at around 80%. The effects of simulated colonic fluid and glutathione on the hydrogel are as follows... Figure 9 As shown, the hydrogel swells continuously in PBS until it reaches swelling equilibrium, while in SCF containing inulinase and glutathione, the 8% IHS hydrogel completely degrades within 80 minutes. Therefore, the gel degrades less in acidic environments, indirectly indicating its ability to resist hydrogen ions and low-pH gastric acid, reducing the intrusion of gastric juice into the hydrogel and thus decreasing the invasion of gastric juice into probiotics and drug-loaded probiotics. Furthermore, it degrades effectively in a reducing environment containing inulinase, promoting the release of drug-loaded probiotics and achieving therapeutic effects.

[0075] Example of effect 4

[0076] This invention discloses the application of an oral probiotic hydrogel in the preparation of drugs for the prevention and treatment of irritable bowel syndrome, diarrhea, constipation, indigestion, inflammatory bowel disease, colon cancer, diabetes, obesity, and hypercholesterolemia. This example examines the protective ability of the hydrogel on probiotics under simulated gastrointestinal conditions and after different storage times after freeze-drying.

[0077] The protective effect of hydrogels on BI (Bifidobacterium) in simulated gastrointestinal conditions.

[0078] BI and a probiotic hydrogel containing an equal amount of BI were placed in 1 mL of SGF, and incubated at 37°C with shaking at 100 rpm for 3 h. Then, the mixture was centrifuged (4500 rpm, 5 min), the SGF was discarded, 1 mL of SIF was added, and the mixture was incubated at 37°C with shaking at 100 rpm for 4 h. After centrifugation, the SIF was discarded, 2 mL of SCF was added, and the mixture was incubated at 37°C with shaking at 100 rpm for 6 h. After 6 h, the mixture was centrifuged, the supernatant was discarded, and the contents were resuspended in sterile PBS and serially diluted. The hydrogel group was completely degraded with dithiothreitol (DTT) and then serially diluted with sterile PBS. An appropriate amount of each dilution was incubated on Bifidobacterium medium for 48 h, and colony counts were performed. The number of surviving bacteria was calculated based on the dilution factor. Figure 10 As shown, the number of live bacteria encapsulated with 6% IHS after treatment with simulated gastrointestinal fluid was 63.8 times that of unencapsulated probiotics, and the number of live bacteria encapsulated with 8% IHS was approximately 80 times that of unencapsulated probiotics. Furthermore, the results of encapsulation and non-encapsulation showed a significant difference, demonstrating that IHS encapsulation can effectively enhance the resistance of probiotics in the gastrointestinal environment.

[0079] The ability of hydrogels to protect BI in bile salts.

[0080] Weigh 250 mg of porcine bile salts and dissolve them completely in 50 mL of sterile water by sonication. Place BI and a hydrogel containing an equal volume of BI in 1 mL of 0.5% bile salts and incubate both at 37°C with shaking at 100 rpm for 4 hours. Centrifuge at fixed intervals and discard the supernatant. Serially dilute the naked bacterial group with sterile PBS after resuspending. Serially dilute the hydrogel group with sterile PBS after degradation with DTT. Incubate appropriate amounts of each dilution on Bifidobacterium medium for 48 hours, count colonies, and calculate bacterial viability based on the dilution factor. Figure 11 As shown, re-incubation in 0.5% bile salt solution for 4 hours reduced the number of surviving naked bacteria by three orders of magnitude. BI bacteria protected by IHS encapsulation, however, exhibited a higher survival rate.

[0081] Study on the survival rate of probiotics in freeze-dried preparations.

[0082] Bifidobacterium bifidum (BI) and probiotic hydrogels containing an equal amount of BI were freeze-dried, and the viable bacterial count before freeze-drying was recorded using the streak plate method. The freeze-dried BI and probiotic hydrogels were stored at -80°C. On days 1, 7, 30, 60, and 90, they were removed, and 1 mL of sterile PBS was added. The solutions were then serially diluted with sterile PBS, and a suitable amount of each dilution was spread onto Bifidobacterium agar. After 48 hours of incubation, colony counting was performed, and the viable bacterial count was calculated based on the dilution factor. Figure 12 As shown, the number of live bacteria in each group gradually decreased over time, with the hydrogel group showing a slightly higher number than the naked bacteria group, indicating that hydrogel encapsulation can enhance the long-term storage stability of probiotics.

[0083] Example 5: Preparation method of oral drug-loaded probiotic hydrogel.

[0084] Preparation of S1 Bifidobacterium infantis-drug-loaded nanocomposite: Taking the anti-tumor drug irinotecan (IRT) as an example, but mixing IRT with probiotics can affect the activity of probiotics. To prevent the reduction of probiotic activity by IRT, IRT is first loaded onto the surface of polydopamine PDA, and then covalently linked to probiotics through Michael addition or Schiff base reaction with the catechol groups of polydopamine to form drug-loaded probiotics. The drug-loaded probiotics are then encapsulated with hydrogel. The specific steps are as follows: IRT solution (20 mg / mL) is added to PDA solution (1 mg / mL) at a drug-to-material ratio of 1:6, and stirred at 800 rpm and 37°C in the dark for 12 h. After the reaction is completed, the mixture is centrifuged at 10,000 rpm for 10 min, the supernatant is discarded, and the precipitate is resuspended in deionized water to obtain polydopamine drug-loaded nanoparticles (PINPs). The drug loading of the nanoparticles was calculated based on the standard curve of drug IRT, and the drug loading was 14.24%, with an encapsulation efficiency of 99.6%.

[0085] Bifidobacterium infantis cultured to the logarithmic growth phase was diluted with sterile water to obtain 1.0 × 10⁻⁶ ppm. 8 -1.0×10 9 The prepared PINPs and BI bacterial solution were mixed and incubated at a certain ratio. After incubation, the mixture was centrifuged to obtain Bifidobacterium infantis-drug-loaded nanocomplex (BI-PI).

[0086] BI-PI was observed using transmission electron microscopy, such as Figure 13 As shown, the BI of the Bifidobacterium infantis-drug-loaded nanoparticle complex is in the shape of a short rod, and the nanoparticles can be seen adsorbed on the surface of the BI, proving that the BI has been successfully loaded with PINPs.

[0087] Preparation of S2 inulin-modified hyaluronic acid; Inulin-modified hyaluronic acid (IH) was prepared using the method described in Example 2.

[0088] S3-thiolated inulin-modified hyaluronic acid; Inulin-modified thiolated hyaluronic acid (IHS) was prepared using the method described in Example 3.

[0089] Preparation of S4 drug-loaded probiotic hydrogel; IHS was placed under a clean bench and irradiated with a UV lamp for 30 minutes. The Bifidobacterium infantis-drug-loaded nanoparticle complex was resuspended in an appropriate amount of sterile water. Then, an appropriate amount of IHS was added, and the mixture was vortexed to mix evenly. After standing, a drug-loaded probiotic hydrogel of appropriate concentration was prepared.

[0090] Example 5 Resistance study of drug-loaded probiotic hydrogels in a simulated gastrointestinal tract.

[0091] Bifidobacterium infantis-drug-loaded nanocomposites (BI-PINPs) and hydrogels containing an equal amount of BI-PINPs were placed in 1 mL of SGF and incubated at 37°C with shaking at 100 rpm for 3 h. Then, the mixture was centrifuged (4500 rpm, 5 min), the SGF was discarded, 1 mL of SIF was added, and the mixture was incubated at 37°C with shaking at 100 rpm for 4 h. After centrifugation, the SIF was discarded, 2 mL of SCF was added, and the mixture was incubated at 37°C with shaking at 100 rpm for 6 h. After 6 h, the mixture was centrifuged, the supernatant was discarded, and the contents were resuspended in sterile PBS and serially diluted. The hydrogel group was completely degraded with DTT and then serially diluted with sterile PBS. A suitable amount of the diluted solution was incubated on Bifidobacterium medium for 48 h, and colony counting was performed. The number of viable bacteria was calculated based on the dilution factor. Figure 14 As shown, IHS encapsulation effectively protects BI-PINPs, with a 72.3-fold increase in the number of surviving BI-PINPs in a simulated gastrointestinal environment compared to unencapsulated BI-PINPs, demonstrating a significant difference. This proves that IHS hydrogel can effectively protect BI-PINPs, reduce the damage to BI-PINPs activity caused by harsh gastrointestinal conditions, and improve the survival rate of probiotics.

[0092] The ability of hydrogels to protect drug-loaded probiotics during storage.

[0093] BI-PINPs and IHS / BI-PINPs containing an equal amount of BI were freeze-dried, and the viable bacterial count before freeze-drying was recorded using the streak plate method. The freeze-dried BI-PINPs and IHS / BI-PINPs were stored at 4°C. On days 7 and 30, they were removed, and 1 mL of sterile PBS was added, followed by serial dilutions with sterile PBS. A suitable amount of each dilution was spread onto Bifidobacterium agar, and after 48 hours of incubation, colony counting was performed. The viable bacterial count was calculated based on the dilution factor. Results are as follows: Figure 15As shown, the number of viable bacteria in each group gradually decreased over time, with the IHS / BI-PINPs group having a slightly higher number than the BI-PINPs group, indicating that the hydrogel has a protective effect on BI.

[0094] Release of orally administered drug-loaded probiotic hydrogels in simulated gastrointestinal and tumor microenvironments.

[0095] The IHS / BI-PINPs hydrogel was placed in a clean dialysis bag, immersed in SGF, and shaken at 100 rpm for 3 hours. Within a certain time, 4 mL of the extradialysis fluid was taken out and quickly replaced with 4 mL of fresh isothermal simulated gastric fluid.

[0096] Replace the original solution, remove the dialysis bag containing hydrogel, place it in SIF and shake at 100 rpm for 4 hours to simulate the small intestine condition, and collect samples in the same manner.

[0097] Replace the original solution, remove the dialysis bag containing hydrogel and place it in a solution containing 10 mM GSH and 10 U / mL inulinase at pH 6.5 to simulate the microenvironment of colon tumors. Shake at 100 rpm and replace the entire solution with fresh isothermal dialysis buffer every 24 hours.

[0098] The absorbance of the sample was measured at the maximum absorbance of the IRT using a UV-Vis spectrophotometer. The concentration and cumulative drug release rate were calculated, and a release curve was plotted. The results are as follows: Figure 16 As shown, in the first 7 hours, when IHS / BI-PINPs were placed in simulated gastric and intestinal fluids, the drug delivery system did not exhibit a burst release under the harsh conditions of the gastrointestinal tract, with a cumulative IRT release of only 12%. However, when IHS / BI-PINPs were placed in a dialysis medium simulating a colon tumor microenvironment, the release of IRT encapsulated in the hydrogel gradually increased, reaching a relative equilibrium at 120 hours, with a cumulative release of 74.16%. These results indicate that the hydrogel can protect the drug-loaded probiotics and prevent drug release in gastric and intestinal fluids, while in the simulated colon tumor microenvironment, the hydrogel can be "disassembled" to effectively release IRT and achieve its therapeutic effect.

[0099] Example 6: To verify the application of drug-loaded probiotic hydrogel, this study presents an in vivo pharmacodynamic study of an oral probiotic drug-loaded hydrogel disclosed in this invention.

[0100] Construction of an orthotopic colorectal cancer mouse model A mouse model of orthotopic colon cancer was established using a cell seeding method. CT26 cell suspensions were collected and resuspended in an equal volume of a mixture of Matrix-Gelm matrix gel and serum-free culture medium at 4°C to disperse the cells to a concentration of 4.0 × 10⁻⁶. 7CT26 cells / mL. Gently shave the hair off the lower abdomen of the mouse with a shaver, inject the CT26 cell suspension into the submucosa of the cecal wall of the shaved mouse, then put the cecum back into the abdomen, and suture the abdominal cavity and skin with No. 7 and No. 5 sutures, respectively.

[0101] In vivo antitumor efficacy analysis of drug-loaded probiotic hydrogels: Mice that successfully developed the model were randomly divided into 5 experimental groups (n=4): a) Saline group, b) Irinotecan group (IRT group), c) Probiotic hydrogel group (IHS / BI group), d) Drug-loaded nanoparticle group (PINPs group), and e) Drug-loaded probiotic hydrogel group (IHS / BI-PINPs group). Each group of mice was administered 0.2 mL of the drug via gavage or oral administration at an IRT dose of 5.0 mg / kg and a concentration of 2.4 × 10⁻⁶ mg / kg. 8 The mice were administered CFU at a BI dose over a 14-day period, with administration every two days and monitoring body weight. Figure 17 As shown, the body weight of mice in the Saline group remained stable without significant changes during the administration period. Mice in the IRT and PINPs groups experienced slight weight decreases, while the body weight of mice in the probiotic-containing formulation group steadily increased and remained relatively stable. This indicates that mice tolerated this dose of IHS / BI-PINPs well.

[0102] Results of metastatic tumor nodules in the gastrointestinal tract of mice after treatment are as follows: Figure 18 , 19 As shown, all treatment groups inhibited the growth and metastasis of intestinal tumors in mice, but the IHS / BI-PINPs group showed a more significant therapeutic effect. The tumor inhibition rate was calculated by measuring the orthotopic colon tumors in mice with calipers, and the results are as follows: Figure 20 As shown, the tumor inhibition rate of the IHS / BI-PINPs group reached 92.12%, and the in situ tumor in one mouse completely disappeared, indicating that IHS / BI-PINPs can effectively inhibit tumors and control tumor growth in the early stage. (In tumor H&E stained sections...) Figure 21 In the study, the tumor structure in the Saline group remained intact, while the tumor in the IHS / BI-PINPs group was significantly destroyed, confirming its good anti-tumor effect.

[0103] Biosafety evaluation of drug-loaded probiotic hydrogels After the in vivo pharmacodynamic experiments were completed, the mice were euthanized and samples of major organs (heart, liver, spleen, lung, and kidney) were collected. H&E staining of the tissues from each organ was used to evaluate the biosafety of IHS / BI-PINPs.

[0104] The results are as follows Figure 22As shown, compared with the Saline group, the cardiac fibroblast structure of mice in the IRT group, PINPs group, IHS / BI group, and IHS / BI-PINPs group was normal in heart sections; liver sections showed clear hepatic lobule structure with no vacuoles in the cytoplasm; spleen sections showed normal red and white pulp structure without congestion or cell atrophy; lung sections showed irregular alveolar structures of inconsistent sizes, and no fibrosis in the lung tissue; kidney sections showed glomerular structure without inflammatory infiltration. These results indicate that none of the formulations produced significant toxic side effects on the major organs of mice, demonstrating good biocompatibility.

[0105] As demonstrated by the above embodiments and effect examples, the oral probiotic hydrogel provided by this invention can effectively encapsulate probiotics in a modified polysaccharide hydrogel, thus solving the technical problem of easy inactivation of oral probiotics in the gastrointestinal environment. This allows for targeted release of probiotics into the colon, improving therapeutic efficacy. The oral probiotic hydrogel of this invention can be used in the preparation of drugs for the prevention and treatment of irritable bowel syndrome, diarrhea, constipation, indigestion, inflammatory bowel disease, colon cancer, diabetes, obesity, and hypercholesterolemia. This verifies that it is feasible to mount drugs or nanomedicines onto probiotics to achieve therapeutic effects for other diseases.

[0106] The preparation method of the present invention is simple to operate, and the prepared product has excellent performance and meets production requirements.

[0107] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can still be made to the technical solutions of the present invention, and these modifications or equivalent substitutions cannot cause the modified technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. An oral probiotic hydrogel, characterized in that, The probiotic hydrogel comprises inulin-modified terminal thiolized polysaccharide hydrogel and probiotics.

2. The oral probiotic hydrogel according to claim 1, characterized in that, The inulin-modified terminal thiolized polysaccharide has the following structural formula: Wherein, R is a repeating unit of a polysaccharide containing a carboxylic acid, and the polysaccharide containing a carboxyl group is one of hyaluronic acid, carboxymethyl chitosan, alginate, pectin, xanthan gum, carboxymethyl cellulose, carboxymethyl glucose, carboxymethyl starch, and chondroitin sulfate.

3. The oral probiotic hydrogel according to claim 1, characterized in that, The probiotic is one of the probiotic subspecies from the genera *Lactobacillus*, *Bifidobacterium*, *Enterococcus*, *Lactococcus lactis*, *Clostridium butyricum*, and *Bacillus*.

4. An oral probiotic hydrogel according to claim 1 or 2, characterized in that, The inulin-modified terminal thiolized polysaccharide was prepared by reacting inulin, polysaccharide, and L-cysteine ​​methyl ester hydrochloride; the molar ratio of carboxyl groups in inulin and polysaccharide was 1:20-1:1; the molar ratio of carboxyl groups to L-cysteine ​​methyl ester hydrochloride in the inulin-modified polysaccharide was 0.1:1-2:

1.

5. A method for preparing an oral probiotic hydrogel, characterized in that, An oral probiotic hydrogel according to any one of claims 1-4, comprising the following steps: S1. The polysaccharide was pretreated, then inulin was added, and the mixture was mixed and reacted under nitrogen for a period of time. After dialysis and freeze-drying, inulin-modified polysaccharide was obtained. S2. After treating the inulin-modified polysaccharide, L-cysteine ​​methyl ester hydrochloride was added, the pH was adjusted, and the mixture was mixed and reacted under nitrogen for a period of time. After the reaction was completed, the mixture was dialyzed and freeze-dried to obtain the inulin-modified thiolated polysaccharide. S3. Resuspend the centrifuged probiotics in sterile water to obtain bacterial solutions of different concentrations. Add the inulin-modified thiolated polysaccharide obtained in S2, mix well, and let stand to prepare probiotic hydrogels of different concentrations.

6. The method for preparing an oral probiotic hydrogel according to claim 5, characterized in that, The pretreatment of polysaccharides in step S1 involves dissolution and activation; the treatment of inulin-modified polysaccharides in step S2 involves dissolution and activation; the solvent in step S1 is dimethyl sulfoxide, the activator is N,N'-carbonyldiimidazole, and the molar ratio of N,N'-carbonyldiimidazole to polysaccharides is 0.3:1-1:1; the solvent in step S2 is water, the activator is N-hydroxysuccinimide (NHS) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCl), the molar ratio of NHS to inulin-modified polysaccharides is 2:1-10:1, and the molar ratio of EDCl to inulin-modified polysaccharides is 2:1-10:

1.

7. A method for preparing an oral probiotic hydrogel according to claim 5 or 6, characterized in that, In step S1, the reaction temperature is 15-25℃ and the reaction time is 12-72h; in step S2, the pH value is adjusted to 3-6, the reaction temperature is 15-25℃, and the reaction is carried out in the dark for 1-4h.

8. The method for preparing an oral probiotic hydrogel according to claim 5, characterized in that, In step S3, the concentration of the probiotic solution is 1×10⁻⁶. 6 ~1×10 10 CFU / ml.

9. The method for preparing oral probiotics according to claim 5, characterized in that, The dialysis conditions in step S1 are: dialysis for 4 days in a dialysis bag (MWCO: 8000-14000Da), freeze-drying for 2 days, and cold trap temperature -60℃; the dialysis in step S2 is: dialysis twice with pH 5.0 hydrochloric acid solution, then once in pH 5.0 hydrochloric acid solution containing 1% (w / v) NaCl, then dialysis twice more with pH 5.0 hydrochloric acid solution, freeze-drying for 1 day, and cold trap temperature -60℃.

10. An application of an oral probiotic hydrogel, characterized in that, The use of the oral probiotic hydrogel according to claim 1 in the preparation of drugs for the prevention and treatment of irritable bowel syndrome, diarrhea, constipation, indigestion, inflammatory bowel disease, colon cancer, diabetes, obesity, and hypercholesterolemia.

Citation Information

Patent Citations

  • Aerogel microcapsule for colon targeted delivery of probiotics and preparation method thereof

    CN116712403A

  • Synbiotic gel microcapsule as well as preparation method and application thereof

    CN119925297A